All Tech Innovators

Peter Wipf

Small Molecule Drug for Targeting Resistant Prostate Cancer

07323

New CPPI-derived small molecules act as nuclear androgen receptor degraders, suppressing resistant prostate cancer in AR-positive tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Timothy James Casad
Joel B. Nelson
Zhou Wang
Date Submitted: 2025-09-02

Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress

03916

Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Hulya Bayir
Robert B. Clark
Tanja Krainz
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-23

A Mechanistic Approach for the Development and Use of Surfactants Containing Drug-Interactive Domains

02645

Tailored surfactants with drug-interactive interfaces enable stable, efficient delivery of moderately hydrophobic drugs.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Tags: Coating
Platform Technology
Lead Inventor: Xiang Gao
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Michael W. Epperly Ph.D.
Xiang Gao
Joel S. Greenberger M.D.
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2011-12-06

Next Generation Targeted Nitroxides

05064

Nitroxide-based lipids curb lipid peroxidation to mitigate ferroptosis, aiming at ischemia injury, AKI, and neuroprotection.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Nephrology
Therapeutic Indications: Acute Kidney Injury (AKI)
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Date Submitted: 2019-07-20
Collections: Cardiometabolic

Antioxidant Therapy for Treating Propionic and Methylmalonic Acidemia

05544

Mitochondria-targeted antioxidants offer a non-invasive therapy to lower reactive oxygen, mitigating damage in propionic and methylmalonic acidemia.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Other
Mitochondrial Disease
Tags: Pediatrics
Rare disease
Lead Inventor: Gerard Vockley
Department: Med-Pediatrics
All Tech Innovators: Gerard Vockley
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-30
Collections: Rare Diseases
Cardiometabolic

Novel Class Therapeutic Psychedelics

05753

Novel clavine psychedelics: total synthesis enables SAR-driven development of non-hallucinogenic, CNS-targeting therapeutic candidates.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Mental and Behavioral Health
Therapeutic Indications: Depression
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Ethan James Pazur
Nikhil Rushi Tasker
Peter Wipf
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-07-02

Novel Carbamates as Treatment for Tinnitus

03415

Potent, selective carbamates target KCNQ2/3 channels to reduce tinnitus and potentially treat epilepsy, via auditory synapse modulation.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Otolaryngology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Athanassios Tzounopoulos
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2014-10-03

Novel Mitochondrial Targeting Nitroxides for Radioprotection and the Treatment of Associated Pathologies

02662

Mitochondria-targeted nitroxide JP4-039 shields tissue from ROS and radiation, aiding healing with topical/oral delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2012-04-11
Collections: Regenerative Medicine
Cardiometabolic

p97 ATPase Inhibitors for Cancer and Neurodegneration

03811

Allosteric p97 inhibitors selectively impair cancer and neurodegenerative pathways by blocking p97 ATPase function.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Donna Huryn
All Tech Innovators: Donna Huryn
Matthew G. LaPorte
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-01-26

A Novel Treatment for Metastatic Prostate Cancer

06044

Novel allosteric AR modulators found to disrupt AR-TIF2 signaling, offering potential treatment for metastatic castration-resistant prostate cancer.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Paul Johnston
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Carlos Jaime Camacho
Andrew P. Hinck
Paul A. Johnston
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-06-01

Novel Thiadiazines as Heat Shock Protein Modulators and Anti-Huntington Disease Therapeutic Agents

05177

Novel thiadiazine modulators target Hsp70, offering potential Huntington and neurodegenerative disease therapies via protein homeostasis regulation.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Jeffrey L. Brodsky Ph.D.
Linh Khai Ngo
Leila Terrab
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-20

Novel Selective Kv7 Channel Modulators

06017

Novel chemotypes selectively modulate Kv7.2 channels, enabling safer, isoform‑specific treatments for epilepsy, tinnitus, and other channelopathies.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Cardiovascular
Tags: Life Science
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-05-02
Collections: Cardiometabolic

Novel Mitochondrial Targeting Nitroxides for Radioprotection and the Treatment of Associated Pathologies

01734

Mitochondria-targeted nitroxide JP4-039 provides radioprotection, reduces ROS damage, and speeds healing with non-invasive delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Valerian Kagan
Department: GSPH-Environmental/Occupational Health
All Tech Innovators: Natalia Alexeevna Belikova
Michael W. Epperly Ph.D.
Joel S. Greenberger M.D.
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2008-05-15
Collections: Regenerative Medicine

HDAC Inhibitors as Anticancer Agents

05372

HDAC-inhibiting chromane-based compounds offer selective anticancer and potential neurodegenerative therapies, advancing epigenetic cancer treatment.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Shikha Singh Chauhan
Desirae Lynn Crocker
Michael James Houghton
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-05-19

Novel carbamates as treatment for tinnitus

04567

Novel carbamates target auditory K-channels (KCNQ2/3) to reduce tinnitus and potentially treat epilepsy with potent, selective action.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Otolaryngology
Tags: Aging
Rare disease
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2018-03-27
Collections: Rare Diseases

Novel Selective NADPH Oxidase 2 Inhibitors

03015

Selective bridged tetrahydroisoquinolines inhibit Nox2, reducing ROS-driven cardiovascular, cancer, and neurological risks with targeted IC50.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Neuroscience
Therapeutic Indications: Parkinson's Disease
Other
Alzheimer's Disease
Tags: Aging
Lead Inventor: Patrick Pagano
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Eugenia Eugenia Cifuentes Pagano
Patrick Joseph Pagano
Erin M. Skoda
Date Submitted: 2013-04-02
Collections: Cardiometabolic

Accelerate Bone Healing Post-Irradiation with MMS350

03622

MMS350 accelerates radiation-related bone healing by scavenging hydroxyl radicals; water-soluble, orally deliverable, non-toxic in mice.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Musculoskeletal
Therapeutic Indications: Bone metabolism
Lead Inventor: Michael Epperly
Department: Med-Radiation Oncology
All Tech Innovators: Michael W. Epperly Ph.D.
Julianne Glowacki Ph.D.
Joel S. Greenberger M.D.
Date Submitted: 2015-05-28
Collections: Regenerative Medicine

Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D

02314

Five to tenfold PKD1 inhibition gains with benzothienothiazepinone/pyrimidine scaffolds; aids anti-cancer tool design and PKD research.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Qiming Jan Wang
Peter Wipf
Date Submitted: 2010-10-06

Use of Targeted Nitroxide Agents in Bone Healing

01966

Mitochondria-targeted nitroxide compounds accelerate bone healing and radioprotection by scavenging ROS with higher potency.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Therapeutic Indications: Bone metabolism
Tags: Critical Care
Lead Inventor: Joel Greenberger
Department: Med-Radiation Oncology
All Tech Innovators: Michael W. Epperly Ph.D.
Abhay S. Gokhale
Joel S. Greenberger M.D.
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2009-04-21
Collections: Regenerative Medicine

Novel Calcium Channel Agonist to Treat Lambert Easton

02841

A novel, use-dependent calcium channel agonist GV-58 shows promise for Lambert-Eaton syndrome, boosting neurotransmitter release with fewer side effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Therapeutic Indications: Parkinson's Disease
Amyotrophic lateral sclerosis (ALS)
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Mary Liang
Stephen D. Meriney
Peter Wipf
Date Submitted: 2012-07-23

MMS350: A Novel Bifunctional Sulfoxide with Radioprotective Effects

02601

MMS350: bifunctional oxetane sulfoxide system boosting drug solubility and providing radiation protection with low toxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Michael W. Epperly Ph.D.
Joel S. Greenberger M.D.
Melissa M. Sprachman
Date Submitted: 2011-10-20